B of A Securities Downgrades Inovio Pharmaceuticals to Underperform, Lowers Price Target to $8
B of A Securities analyst Geoff Meacham downgrades Inovio Pharmaceuticals (NASDAQ:INO) from Neutral to Underperform and lowers the price target from $9 to $8.